Ann arbor stage III lymphocyte-depleted classic Hodgkin lymphoma

Clinical trials for Ann arbor stage III lymphocyte-depleted classic Hodgkin lymphoma explained in plain language.

Never miss a new study

Get alerted when new Ann arbor stage III lymphocyte-depleted classic Hodgkin lymphoma trials appear

Sign up with your email to follow new studies for Ann arbor stage III lymphocyte-depleted classic Hodgkin lymphoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

New combo therapy aims to beat back advanced hodgkin lymphoma

Disease control Ongoing

This phase 3 trial compares two immunotherapy drugs—nivolumab (Opdivo) and brentuximab vedotin (Adcetris)—when added to standard chemotherapy for people aged 12 and older with newly diagnosed stage III or IV classic Hodgkin lymphoma. The goal is to see which combination better de…

Matched conditions: ANN ARBOR STAGE III LYMPHOCYTE-DEPLETED CLASSIC HODGKIN LYMPHOMA

Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Aug 06, 2026 00:00 UTC

Ann arbor stage III lymphocyte-depleted classic Hodgkin lymphoma

Get alerted when new Ann arbor stage III lymphocyte-depleted classic Hodgkin lymphoma trials appear

New combo therapy aims to beat back advanced hodgkin lymphoma